A Novel Cell-based Screening Assay for Cholesterol Biosynthetic Pathway Inhibition Using the RapidFire HTMS Platform

Researchers exploring alternatives to statins for inhibiting the cholesterol synthetic pathway thus turned to CYP51A1 as a potential anticancer target, and antifungal CYP51A1 inhibitor drugs are being tested for anticancer efficacy.

Aragen was commissioned to enable one such project where the client was exploring the possibility of re-purposing an internal collection of antifungal CYP51A1 inhibitors for targeting cancers.

Download our whitepaper to understand how this project went on to yield high potency compounds for the client which allowed them to further their drug discovery plans.

Please fill the form to download the whitepaper